On Wednesday, in the course of current trade, Shares of The Home Depot, Inc. (NYSE:HD), gained 0.21%, and is now trading at $112.58.
The Home Depot, stated sales of $20.9 billion for the first quarter of fiscal 2015, a 6.1 percent enhance from the first quarter of fiscal 2014. Comparable store sales for the first quarter of fiscal 2015 were positive 6.1 percent, and comp sales for U.S. stores were positive 7.1 percent.
Net earnings for the first quarter of fiscal 2015 were $1.6 billion, or $1.21 per diluted share, contrast with net earnings of $1.4 billion, or $1.00 per diluted share, in the same period of fiscal 2014. For the first quarter of fiscal 2015, diluted earnings per share raised 21.0 percent from the same period in the preceding year.
First quarter of fiscal 2015 results reflect a benefit to earnings of $71 million, or $0.05 per diluted share, primarily attributable to the settlement of a tax audit.
The Home Depot, Inc. operates as a home improvement retailer. It operates The Home Depot stores that sell various building materials, home improvement products, and lawn and garden products, in addition to provide installation, home maintenance, and professional service programs to do-it-yourself, do-it-for-me, and professional customers.
During an Afternoon trade, Shares of Visa Inc. (NYSE:V), dipped -0.50%, and is now trading at $69.81.
Visa, declared that more of the Internet’s top merchants will offer Visa Checkout, the online check out service that Visa launched less than a year ago. The newly declared merchants comprise: Dunkin’ Donuts, Fandango, Sundance Catalog and Williams-Sonoma in the U.S.; Pizza Hut, Ticketek and BONDS in Australia; and Indigo, Roots, Running Room and Simons in Canada.
“With screens and keyboards getting smaller and smaller, checking out online must be incredibly simple and easy,” said Sam Shrauger, Visa’s senior vice president of digital solutions. “Visa Checkout offers just that – a fast, easy way to check out in just a few clicks without filling out endless form fields. The early response from consumers and merchants for Visa Checkout has exceeded our expectations and raised our commitment to seeing its acceptance and usage continue to grow on a global scale.”
Visa Inc., a payments technology company, operates as a retail electronic payments network worldwide. The company facilitates commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Shares of Prima Biomed Ltd. (NASDAQ:PBMD), during its Wednesday’s current trading session skyrocketed 221.88%, and is now trading at $5.15, hitting its highest level.
Prima BioMed, declared that the final CVac data from the Phase II CAN-003 ovarian cancer clinical trial has shown a trend for a clinically meaningful improvement in Overall Survival (“OS”) over standard of care (“SOC”) in second remission patients.
In the group of second remission patients (n=20), the median for standard of care (“SOC”) patients was 25.53 months, which is consistent with current literature. By comparison, for patients treated with CVac a median has still not yet been reached after 42 months with study completion and closure. This suggests a striking improvement with a hazard ratio1 = 0.17 (95%CI: 0.02, 1.44; p=0.07). This implies at least a 16 months median survival advantage for second remission patients when treated with CVac.
This data is consistent with the statistically noteworthy Progression Free Survival (“PFS”) data for second remission patients from CAN-003 declared in May 2014 with a median PFS for CVac of greater than 12.91 months, contrast to a median PFS of 4.94 months for the control group (hazard ratio=0.32; p=0.04). This implies an eight month median PFS advantage for second remission patients treated with CVac.
Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product presently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.
Finally, Maxim Integrated Products, Inc. (NASDAQ:MXIM), gained 0.73% Wednesday.
Wearables developers can now right away evaluate galvanic skin response (GSR) sensing with the MAXREFDES73# reference design from Maxim Integrated Products.
Applying GSR (measurement of skin’s conductivity) is a challenge because designers need to manipulate several discrete chips and calibration software before concluding the sensor design. The MAXREFDES73# integrates digital-to-analog (DAC) and analog-to-digital (ADC) converters, a microcontroller with advanced power administration, firmware, and an easy-to-use Android® app into the industry’s first GSR reference design. Now designers of wearables can save development and testing time, and quickly bring their mobile medical and fitness products to market. Offered in a wristband form factor, the MAXREFDES73# comprises body surface temperature readings, Bluetooth® communications, and a rechargeable battery that lasts up to one week on a single charge.
Key Advantages
- Fast time to market: integrates DAC and ADC signal chain components, low-power microcontroller, external Bluetooth and Android apps, and firmware components to quickly develop and test designs
- High accuracy: 16-bit integrated analog front-end (AFE)
- Low power consumption: operates for one week on one battery charge.
Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
